GNC, a struggling vitamin and dietary supplement chain, is hoping to boost its business by targeting people taking GLP-1 drugs for weight loss. The brand announced that it would be adding a dedicated section in its US stores with products specifically tailored for individuals managing GLP-1 medications. GNC is also training its store employees on the common side effects of GLP-1s to better support customers dealing with these issues.
The impact of GLP-1 drugs on people’s health is still not fully understood, but some have reported side effects such as muscle loss and gastrointestinal problems. GNC is positioning itself as a retailer that can help customers managing these side effects by offering specialized products in their new GLP-1 support section. Gyms, food manufacturers, and retailers are also adjusting their strategies to cater to the growing number of people taking GLP-1 medications.
Danish pharmaceutical company Novo Nordisk is profiting greatly from its popular GLP-1 products, with other major pharmaceutical companies like Pfizer and Roche rushing to release their own versions. Health care providers in the US have written over 9 million prescriptions for injectable weight loss drugs like Wegovy in the last three months alone. Researchers estimate that around 30 million people in the US may be taking GLP-1 drugs by 2030, making up about 9% of the population.
Following its bankruptcy filing in 2020 and subsequent store closures, GNC is the latest brand to create a strategy around people taking GLP-1s. Weight loss company WeightWatchers has introduced a new membership plan that gives members access to doctors who can prescribe these medications, as well as investing in a telehealth business to offer virtual prescriptions to patients. Gyms like Life Time and Equinox are also adjusting their offerings to accommodate members taking GLP-1s, with programs designed to preserve muscle mass for those on these medications.
Food companies are preparing for changes in consumer behavior as more people start taking GLP-1 drugs. A report by JPMorgan showed that current GLP-1 users had a decrease in purchases of sugary snacks, soft drinks, and high-carb products compared to those not on the medication. Nestlé, a food giant, is planning to invest more in nutritious products that provide benefits to individuals on GLP-1 treatments, such as their Opifast high-protein shakes. Overall, companies across various industries are adapting their strategies to accommodate the growing number of people taking GLP-1 medications for weight loss.
